Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

被引：2

作者：

Levy, Moshe Yair ^{[1
]}

McGarry, Lisa J. ^{[2
]}

Huang, Hui ^{[2
]}

Lustgarten, Stephanie ^{[2
]}

Nieset, Christopher ^{[2
]}

Haluska, Frank G. ^{[2
]}

机构：

[1] Baylor Univ, Med Ctr, Dallas, TX USA

[2] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.3154.3154

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) ANALYSIS FOR PONATINIB VS BOSUTINIB IN THIRD-LINE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
Iannazzo, S.
McGarry, L.
Lustgarten, S.
Chiroli, S.
VALUE IN HEALTH, 2016, 19 (07) : A577 - A577
[2] Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
Cortes, Jorge
Kantarjian, Hagop M.
Richard-Carpentier, Guillaume
Borthakur, Gautam M.
Ravandi, Farhad
Naqvi, Kiran
Sasaki, Koji
Kadia, Tapan M.
Verstovsek, Srdan
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Pemmaraju, Naveen
Daver, Naval G.
Bose, Prithviraj
Pierce, Sherry A.
Dara, Samuel
Jabbour, Elias
Cortes, Jorge E.
BLOOD, 2019, 134
[3] Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
Dahlen, Torsten
Kockerols, Camille C. B.
Ferreira, Germano
Westerweel, Peter E.
Mayer, Jiri
Allepuz, Alex
Wormser, David
Yau, Lillian
Zackova, Daniela
BLOOD, 2022, 140 : 3889 - 3890
[4] Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Levy, Moshe Yair
McGarry, Lisa J.
Huang, Hui
Lustgarten, Stephanie
Chiroli, Silvia
Iannazzo, Sergio
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (03) : 479 - 487
[5] Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
Hochhaus, Andreas
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck Emmanuel
Talpaz, Moshe
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Castagnetti, Fausto
Milojkovic, Dragana
Lustgarten, Stephanie
Rivera, Victor M.
Neumann, Frank
Guilhot, Francois
Deininger, Michael W.
Hughes, Timothy P.
Shah, Neil P.
Kantarjian, Hagop M.
BLOOD, 2017, 130
[6] Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
Kantarjian, Hagop M.
Deininger, Michael W.
Abruzzese, Elisabetta
Apperley, Jane
Cortes, Jorge E.
Chuah, Charles
DeAngelo, Daniel J.
DiPersio, John F.
Hochhaus, Andreas
Lipton, Jeffrey H.
Nicolini, Franck E.
Ibarz, Javier Pinilla
Rea, Delphine
Rosti, Gianantonio
Rousselot, Philippe
Shah, Neil P.
Talpaz, Moshe
Srivastava, Shouryadeep
Lu, Vickie
Mauro, Michael J.
BLOOD, 2020, 136
[7] Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
Kong, Jee Hyun
Winton, Elliott F.
Heffner, Leonard
Gaddh, Manila
Hill, Brittany
Arellano, Martha L.
El-Rassi, Fuad
Kim, Audrey
Kota, Vamsi
BLOOD, 2017, 130
[8] Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs.
Ibrahim, Amr R.
Bua, Marco
Khorshad, Jamshid S.
Milojkovic, Dragana
Eliasson, Lina
Szydlo, Richard
Foroni, Letizia
Reid, Alistair
de Lavallade, Hugues
Rezvani, Katayoun
Goldman, John M.
Apperley, Jane
Marin, David
BLOOD, 2010, 116 (21) : 936 - 936
[9] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Rea, Delphine
Hochhaus, Andreas
Mauro, Michael J.
Minami, Yosuke
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna
Kim, Wook
Apperley, Jane F.
Cortes, Jorge E.
Abdo, Andre
Fogliatto, Laura Marie
Kim, Dennis Dong Hwan
le Coutre, Philipp
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem
Chee, Lynette
Garcia-Gutierrez, Valentin
Sasaki, Koji
Kapoor, Shruti
Allepuz, Alex
Quenet, Sara
Bedoucha, Veronique
Boquimpani, Carla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
[10] Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
Kim, Dong-Wook
Cortes, Jorge E.
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →